The combination of trastuzumab, pertuzumab, and a taxane is recommended as first-line treatment for patients with HER2-positive breast cancer, for up to six cycles of taxane therapy, unless contraindicated (expert recommendation). The gene discussed is ERBB2; the disease is breast cancer.